

# Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date November 19, 2010

Frontier Building, 3601 C Street; Room 890/896

## Agenda

Call in: 1-800-315-6338. Use access code 735#.

**DRAFT**

Call to Order – Chair Richard Brodsky, MD

8:00 am

Roll Call

8:05 am

Public Comment - (See guidelines on page 2)

Local Public / Health Practitioners

The Department has developed a new method for class review to better utilize the time of the P&T Committee. Three sets of classes are up for review. Classes shown in **Red** are new classes or classes where new information exists and public testimony will be taken. Classes shown in **Blue** will be reviewed only if new information is received, then public testimony will be taken. For the classes shown in **Green**, no changes have been noted and no public testimony will be taken. New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

Public Comment on Blue/Red Classes	
Discussion & vote on <b>Red Classes</b>	
The Department will review the following <b>red classes</b> as the classes are new or new information exists.	
<b>*Review Tramadol Agents</b>	<b>*Re-Review Statins</b>
<b>*Review Long Acting Injectable Antipsychotics</b>	<b>*Review Suboxone</b>
<b>*Review Selective Constipation Agent</b>	
The Department proposes no changes to the P&T Committee's clinical recommendation in the following <b>blue classes</b> unless new information is received.	
<b>Re-Review Long Acting Opioids</b>	<b>Re-Review Fentanyl, Buccal</b>
<b>Re-Review Anticonvulsants, 1st Generation</b>	<b>Re-Review Anticonvulsants, 2nd Generation</b>
<b>Re-Review SNRI's</b>	<b>Re-Review Atypical Antipsychotics</b>
<b>Re- Review Progestins Used For Cachexia</b>	<b>Re-Review H2RA's</b>
<b>Re-Review PPI's</b>	<b>Re-Review Urinary Tract Antispasmodics</b>
The Department proposes no changes to the P&T Committee's clinical recommendation to the following classes as shown in <b>green</b> .	
<b>Re-Review COX-2 Inhibitor</b>	<b>Re- Review Skeletal Muscle Relaxants</b>
<b>Re-Review Other Antidepressants</b>	<b>Re-Review SSRI's</b>
<b>Re-Review Sedative Hypnotics</b>	<b>Re-Review ADD/ADHD</b>
<b>Re-Review Growth Hormone</b>	
Break as needed – 15 minutes -	
Review minutes from September 2010 meeting	
Comments from Committee Members or Chair	
Adjourn	

Future Meeting Dates: January 21, 2011, and April 15, 2011

**GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE**  
**November 19, 2010**

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted Magellan Medicaid Administration prior to the meeting.